EP3925608A3 - Utilisation de composés de phénoxypropylamine pour traiter ou améliorer au moins un trouble ou paramètre du sommeil - Google Patents

Utilisation de composés de phénoxypropylamine pour traiter ou améliorer au moins un trouble ou paramètre du sommeil Download PDF

Info

Publication number: EP3925608A3
Authority: EP; European Patent Office
Prior art keywords: compositions; formula; disclosed; methods; sleep
Prior art date: 2013-01-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21171312.8A

Other languages

German (de)

English (en)

Other versions

EP3925608A2 (fr

Inventor

Lorenzo Pellegrini

Argeris Karabelas

Remy LUTHRINGER

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Minerva Neurosciences Inc

Original Assignee

Minerva Neurosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-24

Filing date

2014-01-24

Publication date

2022-01-19

2014-01-24 Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc

2021-12-22 Publication of EP3925608A2 publication Critical patent/EP3925608A2/fr

2022-01-19 Publication of EP3925608A3 publication Critical patent/EP3925608A3/fr

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP21171312.8A 2013-01-24 2014-01-24 Utilisation de composés de phénoxypropylamine pour traiter ou améliorer au moins un trouble ou paramètre du sommeil Pending EP3925608A3 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201361756208P	2013-01-24	2013-01-24
US201361852149P	2013-03-15	2013-03-15
US201361799482P	2013-03-15	2013-03-15
EP14743158.9A EP2948143B1 (fr)	2013-01-24	2014-01-24	Utilisation de composés de phénoxypropylamine pour traiter la dépression
PCT/US2014/013026 WO2014117003A1 (fr)	2013-01-24	2014-01-24	Utilisation de composés de phénoxypropylamine pour traiter la dépression

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14743158.9A Division EP2948143B1 (fr)	2013-01-24	2014-01-24	Utilisation de composés de phénoxypropylamine pour traiter la dépression

Publications (2)

Publication Number	Publication Date
EP3925608A2 EP3925608A2 (fr)	2021-12-22
EP3925608A3 true EP3925608A3 (fr)	2022-01-19

Family

ID=51208168

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP21171312.8A Pending EP3925608A3 (fr)	2013-01-24	2014-01-24	Utilisation de composés de phénoxypropylamine pour traiter ou améliorer au moins un trouble ou paramètre du sommeil
EP14743158.9A Active EP2948143B1 (fr)	2013-01-24	2014-01-24	Utilisation de composés de phénoxypropylamine pour traiter la dépression

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP14743158.9A Active EP2948143B1 (fr)	2013-01-24	2014-01-24	Utilisation de composés de phénoxypropylamine pour traiter la dépression

Country Status (23)

Country	Link
US (3)	US20140206722A1 (fr)
EP (2)	EP3925608A3 (fr)
JP (2)	JP6422890B2 (fr)
KR (4)	KR102587177B1 (fr)
CN (2)	CN110664813A (fr)
AU (4)	AU2014209200B2 (fr)
BR (1)	BR112015017628A2 (fr)
CA (2)	CA2898279C (fr)
CL (1)	CL2015002069A1 (fr)
DK (1)	DK2948143T3 (fr)
ES (1)	ES2875058T3 (fr)
IL (4)	IL311363A (fr)
MX (2)	MX388354B (fr)
MY (1)	MY185908A (fr)
NZ (2)	NZ709967A (fr)
PE (1)	PE20151888A1 (fr)
PH (1)	PH12015501643A1 (fr)
PL (1)	PL2948143T3 (fr)
PT (1)	PT2948143T (fr)
RU (2)	RU2020120236A (fr)
SG (2)	SG11201505737YA (fr)
WO (1)	WO2014117003A1 (fr)
ZA (2)	ZA201505114B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201808285A (zh) *	2016-05-25	2018-03-16	田邊三菱製藥股份有限公司	焦慮症處置用組成物及處置方法
US11541201B2 (en) *	2017-10-04	2023-01-03	Neurogeneces, Inc.	Sleep performance system and method of use
US11766430B2 (en)	2018-09-04	2023-09-26	Minerva Neurosciences, Inc.	Methods of using a phenoxypropylamine compound to treat pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4207343A (en) *	1978-06-22	1980-06-10	Eli Lilly And Company	1-Phenyl-3-(substituted phenoxy)propylamines
WO2001046179A1 (fr) *	1999-12-20	2001-06-28	Eli Lilly And Company	Derives de piperidine et leur utilisation comme antagonistes du recepteur de la serotonine
US20040138227A1 (en) *	1999-05-24	2004-07-15	Akira Nishiyama	Phenoxypropylamine compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2424799C1 (ru) *	2010-03-29	2011-07-27	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ"	Способ коррекции депрессивных расстройств производными тиетан-1,1-диоксида в эксперименте

2014
- 2014-01-24 ES ES14743158T patent/ES2875058T3/es active Active
- 2014-01-24 RU RU2020120236A patent/RU2020120236A/ru unknown
- 2014-01-24 BR BR112015017628A patent/BR112015017628A2/pt not_active Application Discontinuation
- 2014-01-24 EP EP21171312.8A patent/EP3925608A3/fr active Pending
- 2014-01-24 MX MX2018011493A patent/MX388354B/es unknown
- 2014-01-24 NZ NZ709967A patent/NZ709967A/en unknown
- 2014-01-24 JP JP2015555358A patent/JP6422890B2/ja active Active
- 2014-01-24 SG SG11201505737YA patent/SG11201505737YA/en unknown
- 2014-01-24 CA CA2898279A patent/CA2898279C/fr active Active
- 2014-01-24 WO PCT/US2014/013026 patent/WO2014117003A1/fr not_active Ceased
- 2014-01-24 IL IL311363A patent/IL311363A/en unknown
- 2014-01-24 KR KR1020227026625A patent/KR102587177B1/ko active Active
- 2014-01-24 EP EP14743158.9A patent/EP2948143B1/fr active Active
- 2014-01-24 DK DK14743158.9T patent/DK2948143T3/da active
- 2014-01-24 PE PE2015001552A patent/PE20151888A1/es not_active Application Discontinuation
- 2014-01-24 NZ NZ750189A patent/NZ750189A/en unknown
- 2014-01-24 RU RU2015135358A patent/RU2725112C2/ru active
- 2014-01-24 US US14/163,827 patent/US20140206722A1/en not_active Abandoned
- 2014-01-24 PT PT147431589T patent/PT2948143T/pt unknown
- 2014-01-24 CN CN201910816861.XA patent/CN110664813A/zh active Pending
- 2014-01-24 AU AU2014209200A patent/AU2014209200B2/en active Active
- 2014-01-24 KR KR1020207019380A patent/KR102247960B1/ko active Active
- 2014-01-24 KR KR1020217011567A patent/KR20210047368A/ko not_active Ceased
- 2014-01-24 PL PL14743158T patent/PL2948143T3/pl unknown
- 2014-01-24 CA CA3150231A patent/CA3150231A1/fr active Pending
- 2014-01-24 MX MX2015009445A patent/MX2015009445A/es unknown
- 2014-01-24 IL IL287727A patent/IL287727B2/en unknown
- 2014-01-24 MY MYPI2015001864A patent/MY185908A/en unknown
- 2014-01-24 SG SG10201706035QA patent/SG10201706035QA/en unknown
- 2014-01-24 KR KR1020157022424A patent/KR102172351B1/ko active Active
- 2014-01-24 CN CN201480017774.3A patent/CN105377255A/zh active Pending
2015
- 2015-07-14 IL IL239928A patent/IL239928B/en active IP Right Grant
- 2015-07-16 ZA ZA2015/05114A patent/ZA201505114B/en unknown
- 2015-07-24 PH PH12015501643A patent/PH12015501643A1/en unknown
- 2015-07-24 CL CL2015002069A patent/CL2015002069A1/es unknown
2018
- 2018-06-19 JP JP2018116163A patent/JP6657315B2/ja active Active
2019
- 2019-01-25 AU AU2019200512A patent/AU2019200512B2/en active Active
2020
- 2020-03-25 US US16/829,657 patent/US20200223838A1/en not_active Abandoned
- 2020-07-15 AU AU2020205268A patent/AU2020205268B2/en active Active
- 2020-10-18 IL IL278109A patent/IL278109B/en unknown
2022
- 2022-07-07 ZA ZA2022/07530A patent/ZA202207530B/en unknown
- 2022-09-26 AU AU2022241458A patent/AU2022241458B2/en active Active
2024
- 2024-07-05 US US18/764,714 patent/US20250109127A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4207343A (en) *	1978-06-22	1980-06-10	Eli Lilly And Company	1-Phenyl-3-(substituted phenoxy)propylamines
US20040138227A1 (en) *	1999-05-24	2004-07-15	Akira Nishiyama	Phenoxypropylamine compounds
WO2001046179A1 (fr) *	1999-12-20	2001-06-28	Eli Lilly And Company	Derives de piperidine et leur utilisation comme antagonistes du recepteur de la serotonine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL MANSARI M ET AL: "In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 376, no. 5, 30 November 2007 (2007-11-30), pages 351 - 361, XP019584490, ISSN: 1432-1912 *
NUTT DAVID ET AL: "Sleep disorders as core symptoms of depression.", DIALOGUES IN CLINICAL NEUROSCIENCE 2008, vol. 10, no. 3, 2008, pages 329 - 336, XP002761112, ISSN: 1294-8322 *
PAPP M ET AL: "P.2.b.008 Antidepressant-like activity of Wf-516, an antagonist of 5-HT1A receptors and inhibitor of 5-HT reuptake, in a chronic mild stress model of depression in rat", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL, vol. 16, 1 January 2006 (2006-01-01), pages S305 - S306, XP027969671, ISSN: 0924-977X, [retrieved on 20060101] *
TAKEAKI SAIJO ET AL: "Presynaptic Selectivity of a Ligand for Serotonin 1A Receptors Revealed by In Vivo PET Assays of Rat Brain", PLOS ONE, vol. 7, no. 8, 7 August 2012 (2012-08-07), pages e42589, XP055297335, DOI: 10.1371/journal.pone.0042589 *

Also Published As

Publication number	Publication date
IL287727A (en)	2021-12-01
NZ750189A (en)	2020-08-28
IL239928B (en)	2021-04-29
KR20220112865A (ko)	2022-08-11
PH12015501643B1 (en)	2015-10-12
EP2948143B1 (fr)	2021-05-05
AU2019200512A1 (en)	2019-02-14
IL278109B (en)	2022-03-01
JP2016510331A (ja)	2016-04-07
IL239928A0 (en)	2015-08-31
JP2018172400A (ja)	2018-11-08
KR102247960B1 (ko)	2021-05-07
AU2020205268A1 (en)	2020-08-06
AU2014209200B2 (en)	2018-11-01
US20140206722A1 (en)	2014-07-24
AU2019200512B2 (en)	2020-04-16
JP6657315B2 (ja)	2020-03-04
PH12015501643A1 (en)	2015-10-12
SG11201505737YA (en)	2015-08-28
KR20200086377A (ko)	2020-07-16
CL2015002069A1 (es)	2016-05-20
EP2948143A1 (fr)	2015-12-02
AU2022241458B2 (en)	2024-11-14
RU2015135358A (ru)	2017-03-03
CA3150231A1 (fr)	2014-07-31
MY185908A (en)	2021-06-14
ZA202207530B (en)	2023-10-25
CA2898279C (fr)	2022-05-17
WO2014117003A1 (fr)	2014-07-31
SG10201706035QA (en)	2017-08-30
MX388354B (es)	2025-03-19
KR102587177B1 (ko)	2023-10-06
CN105377255A (zh)	2016-03-02
IL287727B2 (en)	2024-08-01
US20250109127A1 (en)	2025-04-03
IL287727B1 (en)	2024-04-01
RU2725112C2 (ru)	2020-06-29
IL278109A (en)	2020-11-30
PT2948143T (pt)	2021-06-03
KR102172351B1 (ko)	2020-11-02
CN110664813A (zh)	2020-01-10
BR112015017628A2 (pt)	2017-07-11
IL311363A (en)	2024-05-01
DK2948143T3 (da)	2021-07-26
ES2875058T3 (es)	2021-11-08
EP3925608A2 (fr)	2021-12-22
KR20150120987A (ko)	2015-10-28
AU2022241458A1 (en)	2022-10-20
US20200223838A1 (en)	2020-07-16
NZ709967A (en)	2020-05-29
RU2020120236A (ru)	2020-09-01
PE20151888A1 (es)	2016-01-13
AU2020205268B2 (en)	2022-07-07
JP6422890B2 (ja)	2018-11-14
AU2014209200A1 (en)	2015-07-30
MX2015009445A (es)	2016-01-14
CA2898279A1 (fr)	2014-07-31
KR20210047368A (ko)	2021-04-29
ZA201505114B (en)	2023-09-27
PL2948143T3 (pl)	2021-12-13
EP2948143A4 (fr)	2017-02-22

Publication	Publication Date	Title
PH12018502125A1 (en)	2019-03-25	Bipyrazole derivatives as jak inhibitors
EA033689B9 (ru)	2020-04-29	Ингибиторы g12c kras
MX364155B (es)	2019-04-12	Sulfonamidas como moduladores de canales de sodio.
NZ711424A (en)	2020-03-27	Pyridine derivatives as soft rock inhibitors
MY186547A (en)	2021-07-26	4?-fluoro-2?-methyl substituted nucleoside derivatives
IN2014DN09434A (fr)	2015-07-17
UA117032C2 (uk)	2018-06-11	Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
HK1215579A1 (zh)	2016-09-02	被取代的2，3-二氫苯並呋喃基化合物和其用途
MX2016005760A (es)	2016-07-18	Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
CA2878796C (fr)	2018-10-23	Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
UA115357C2 (uk)	2017-10-25	Похідні піридин-4-ілу
EA032271B9 (ru)	2019-08-30	Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12015501643B1 (en)	2015-10-12	Methods of use of phenoxypropylamine compounds to treat depression
WO2012173382A3 (fr)	2013-03-14	Composition à usage externe pour l'épiderme, contenant du tanshinone ii a en tant que principe actif
MY162945A (en)	2017-07-31	Azole derivative
PH12017501736B1 (en)	2022-07-22	Indole derivatives
EA201500446A1 (ru)	2016-05-31	Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX2023006909A (es)	2023-06-26	Metodos de uso de compuestos de fenoxipropilamina para tratar la depresion.
PH12015502703A1 (en)	2016-03-14	Pharmaceutical compositions
WO2014147636A8 (fr)	2014-12-04	Dérivés 5-amino-quinoline-8-carboxamides en tant qu'agonistes du récepteur 5-ht4
TH158821A (th)	2016-12-26	วิธีการของการใช้งานของสารประกอบฟีนอกซีโพรพิลเอมีน เพื่อบำบัดภาวะซึมเศร้า

Legal Events

Date	Code	Title	Description
2021-11-19	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-11-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2021-12-17	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2021-12-22	AC	Divisional application: reference to earlier application	Ref document number: 2948143 Country of ref document: EP Kind code of ref document: P
2021-12-22	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-01-19	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-01-19	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 43/00 20060101ALI20211214BHEP Ipc: A61P 25/20 20060101ALI20211214BHEP Ipc: A61P 25/00 20060101ALI20211214BHEP Ipc: A61K 31/352 20060101ALI20211214BHEP Ipc: A61K 31/4025 20060101ALI20211214BHEP Ipc: A61K 31/4245 20060101AFI20211214BHEP
2022-07-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-08-24	17P	Request for examination filed	Effective date: 20220718
2022-08-24	RBV	Designated contracting states (corrected)	Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-11-22	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MINERVA NEUROSCIENCES, INC.
2024-12-18	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-12-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2025-01-22	INTG	Intention to grant announced	Effective date: 20241219
2025-01-22	RIN1	Information on inventor provided before grant (corrected)	Inventor name: LUTHRINGER, REMY Inventor name: KARABELAS, ARGERIS Inventor name: PELLEGRINI, LORENZO
2025-04-15	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2025-04-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2025-05-21	INTC	Intention to grant announced (deleted)
2025-06-11	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2025-06-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2025-07-16	INTG	Intention to grant announced	Effective date: 20250612